Literature DB >> 24935473

Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer.

Tian-Yi Wang1, Yin-Peng Huang, Ping Ma.   

Abstract

The aim of this study was to identify the correlations of a common polymorphism (rs6774494 A > G) in the EVI-1 gene targeted by micro-RNA (miRNA)-206/133b with the pathogenesis of breast cancer (BC). A total of 196 unrelated ethnic Han Chinese women diagnosed with primary BC were consecutively recruited and 200 healthy controls were randomly selected from the same population-based cohort. Direct PCR sequencing assay was used to detection of rs6774494 A > G polymorphism in the EVI-1 gene. Real-time quantitative PCR (RT-PCR) analysis was performed to verify the alterations of the EVI1 messenger RNA (mRNA) levels. Kaplan-Meier analysis was used to investigate and to estimate the survival outcomes for each endpoint. All statistical analyses were performed with SPSS software (version 18.0, SPSS, Chicago, IL). Our results demonstrated that the carriers of EVI-1 AG genotype were more likely to develop BC when compared with the EVI-1 GG genotype (P = 0.034, OR = 1.26, 95% CI = 1.02 ∼ 1.57). In addition, it was found that patients with the G (AG + GG) allele of EVI-1 genetic variants were associated with higher risk of BC compared with the EVI-1 AA genotype (OR = 1.26, 95% CI = 1.02 ∼ 1.54, P = 0.028). The results of a subgroup analysis stratified by menopause revealed that in female post-menopause subgroup patients with the EVI-1 G allele were correlated with a higher risk of BC than those with the EVI-1 AA genotype (OR = 1.31, 95% CI = 1.00 ∼ 1.72, P = 0.054). Kaplan-Meier analyses suggested that carriers of the G allele (AG + GG) were associated with poorer overall survival (OS) and progression-free survival (PFS) compared with those with AA genotype (OS P = 0.042; PFS P = 0.036, respectively). The correlation analysis showed that EVI-1 mRNA levels were negatively associated with miRNA-206/133b levels in the carriers of the G allele (AG + GG) (r = -1.274, P < 0.05). Our findings provide evidence that the EVI-1 rs6774494 G > A polymorphism targeted by miRNA-206/133b may contribute to the pathogenesis of BC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935473     DOI: 10.1007/s13277-014-2213-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts.

Authors:  A Kilbey; C Bartholomew
Journal:  Oncogene       Date:  1998-04-30       Impact factor: 9.867

2.  Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.

Authors:  J B Patel; H N Appaiah; R M Burnett; P Bhat-Nakshatri; G Wang; R Mehta; S Badve; M J Thomson; S Hammond; P Steeg; Y Liu; H Nakshatri
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 3.  The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis.

Authors:  Takeshi Imamura; Atsuhiko Hikita; Yasumichi Inoue
Journal:  Breast Cancer       Date:  2011-12-03       Impact factor: 4.239

Review 4.  MicroRNA-mediated breast cancer metastasis: from primary site to distant organs.

Authors:  L Wang; J Wang
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

Review 5.  The role of EVI1 in normal and leukemic cells.

Authors:  Silvia Buonamici; Soumen Chakraborty; Vitalyi Senyuk; Giuseppina Nucifora
Journal:  Blood Cells Mol Dis       Date:  2003 Sep-Oct       Impact factor: 3.039

6.  Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.

Authors:  Tair Kontorovich; Asaf Levy; Michael Korostishevsky; Uri Nir; Eitan Friedman
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

7.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.

Authors:  Naoto Kondo; Tatsuya Toyama; Hiroshi Sugiura; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT.

Authors:  Y Liu; L Chen; T C Ko; A P Fields; E A Thompson
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

9.  Effect of obesity and other lifestyle factors on mortality in women with breast cancer.

Authors:  Luigino Dal Maso; Antonella Zucchetto; Renato Talamini; Diego Serraino; Carmen F Stocco; Marina Vercelli; Fabio Falcini; Silvia Franceschi
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

10.  New functions for ecotropic viral integration site 1 (EVI1), an oncogene causing aggressive malignant disease.

Authors:  Rotraud Wieser
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

View more
  4 in total

1.  miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.

Authors:  Haruna Yamamoto; Jun Lu; Shigeyoshi Oba; Toyotaka Kawamata; Akihide Yoshimi; Natsumi Kurosaki; Kazuaki Yokoyama; Hiromichi Matsushita; Mineo Kurokawa; Arinobu Tojo; Kiyoshi Ando; Kazuhiro Morishita; Koko Katagiri; Ai Kotani
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

2.  Thrombocytopenia in solid tumors: Prognostic significance.

Authors:  Majid Ghanavat; Mina Ebrahimi; Hassan Rafieemehr; Mahmood Maniati; Masumeh Maleki Behzad; Saeid Shahrabi
Journal:  Oncol Rev       Date:  2019-05-14

3.  Ecotropic virus integration-1 and calreticulin as novel prognostic markers in triple-negative breast cancer: A retrospective cohort study.

Authors:  Dongning He; Lei Wu; Xiaoxi Li; Xiaodan Liu; Ping Ma; Youhong Juang
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

4.  Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme.

Authors:  Aiwu Hou; Lizhen Zhao; Fuzhen Zhao; Weiliang Wang; Jianyi Niu; Bingxuan Li; Zhongjin Zhou; Dongyuan Zhu
Journal:  Onco Targets Ther       Date:  2016-01-13       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.